25 results on '"Cetinkaya R"'
Search Results
2. EHMTI-0353. MR tractography in short lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing (SUNCT) patients: case reports
- Author
-
Coskun, O, Ucar, M, Yildirim, F, Cetinkaya, R, and Bolay, H
- Published
- 2014
- Full Text
- View/download PDF
3. Demographic and clinical characteristics of patients with autosomal dominant polycystic kidney disease: a multicenter experience
- Author
-
Kazancioglu, RÜMEYZA, Ecder, T, Altintepe, L, Altiparmak, MR, Tuglular, S, Uyanik, A, Cavdar, C, Ecder, SA, Tokgoz, B, Duman, N, Duzova, A, Cetinkaya, R, Turkish, Society, and KAZANCIOĞLU, RÜMEYZA
- Published
- 2011
4. DIALYSIS BONE DISEASE
- Author
-
Fusaro, M., primary, Giannini, S., additional, Miozzo, D., additional, Noale, M., additional, Tripepi, G., additional, Plebani, M., additional, Zaninotto, M., additional, Piccoli, A., additional, Vilei, M. T., additional, Cristofaro, R., additional, Gallieni, M., additional, Hamamoto, K., additional, Inaba, M., additional, Okuno, S., additional, Imanishi, Y., additional, Ishimura, E., additional, Yamakawa, T., additional, Shoji, S., additional, Rothe, H. M., additional, Eller, P., additional, Mayer, G., additional, Ketteler, M., additional, Kramar, R., additional, Shaheen, F., additional, Al Rukhaimi, M., additional, Alsahow, A., additional, Al-Ali, F., additional, Al Salmi, I., additional, Al Ghareeb, S., additional, Wang, M., additional, Bieber, B., additional, Robinson, B. M., additional, Pisoni, R. L., additional, Waniewski, J., additional, Debowska, M., additional, Wojcik-Zaluska, A., additional, Ksiazek, A., additional, Zaluska, W., additional, De Broe, M. E., additional, Wilson, R. J., additional, Copley, J. B., additional, Hiramtasu, R., additional, Ubara, Y., additional, Hoshino, J., additional, Takaichi, K., additional, Ghalli, F. G., additional, Ibakkanavar, R., additional, Chess, J., additional, Roberts, G., additional, Riley, S., additional, Oliveira, A. S. A., additional, Carvalho, C. J. B., additional, Oliveira, C. B. L., additional, Pessoa, C. T. B. C., additional, Leao, R. A. S., additional, Gueiros, J. E. B., additional, Gueiros, A. P. S., additional, Okano, K., additional, Tsuruta, Y., additional, Hibi, A., additional, Tsukada, M., additional, Miwa, N., additional, Kimata, N., additional, Tsuchiya, K., additional, Akiba, T., additional, Nitta, K., additional, Mizobuchi, M., additional, Ogata, H., additional, Hosaka, N., additional, Sanada, D., additional, Arai, N., additional, Koiwa, F., additional, Kinugasa, E., additional, Shibata, T., additional, Akizawa, T., additional, Delanaye, P., additional, Krzesinski, J.-M., additional, Warling, X., additional, Moonen, M., additional, Smelten, N., additional, Medart, L., additional, Pottel, H., additional, Cavalier, E., additional, Souberbielle, J.-C., additional, Gadisseur, R., additional, Dubois, B. E., additional, Matias, P., additional, Jorge, C., additional, Mendes, M., additional, Azevedo, A., additional, Navarro, D., additional, Ferreira, C., additional, Amaral, T., additional, Aires, I., additional, Gil, C., additional, Ferreira, A., additional, Kikuchi, H., additional, Shimada, H., additional, Karasawa, R., additional, Suzuki, M., additional, An, W. S., additional, Lee, S. M., additional, Oh, Y. J., additional, Son, Y. K., additional, De Paola, L., additional, Lombardi, G., additional, Panzino, M. T., additional, Lombardi, L., additional, Reichel, H., additional, Hahn, K.-M., additional, Kohnle, M., additional, Guggenberger, C., additional, Delanna, F., additional, Sasaki, N., additional, Tsunoda, M., additional, Ikee, R., additional, Hashimoto, N., additional, Sola, L., additional, Leyun, M. N., additional, Diaz, J. C., additional, Sehabiague, C., additional, Gonzalez, S., additional, Alallon, W., additional, Bourbeau, K., additional, Lajoie, C., additional, Macway, F., additional, Fujii, T., additional, Suzuki, S., additional, Shinozaki, M., additional, Tanaka, H., additional, Klingele, M., additional, Seiler, S., additional, Poppleton, A., additional, Lepper, P., additional, Fliser, D., additional, Seidel, R., additional, Lun, L., additional, Liu, D., additional, Li, X., additional, Wei, X., additional, Miao, J., additional, Gao, Z., additional, Hu, R., additional, Gros, B., additional, Galan, A., additional, Gonzalez-Parra, E., additional, Herrero, J. A., additional, Echave, M., additional, Vegter, S., additional, Tolley, K., additional, Oyaguez, I., additional, Gutzwiller, F. S., additional, Braunhofer, P. G., additional, Szucs, T. D., additional, Schwenkglenks, M., additional, Yilmaz, V. T., additional, Ozdem, S., additional, Donmez, L., additional, Kocak, H., additional, Dinckan, A., additional, Cetinkaya, R., additional, Suleymanlar, G., additional, and Ersoy, F. F., additional
- Published
- 2014
- Full Text
- View/download PDF
5. TRANSPLANTATION CLINICAL 1
- Author
-
Schachtner, T., primary, Reinke, P., additional, Dorje, C., additional, Mjoen, G., additional, Midtvedt, K., additional, Strom, E. H., additional, Oyen, O., additional, Jenssen, T., additional, Reisaeter, A. V., additional, Smedbraaten, Y. V., additional, Sagedal, S., additional, Fagerland, M. W., additional, Hartmann, A., additional, Thiel, S., additional, Zulkarnaev, A., additional, Vatazin, A., additional, Vincenti, F., additional, Harel, E., additional, Kantor, A., additional, Thurison, T., additional, Hoyer-Hansen, G., additional, Craik, C., additional, Kute, V. B., additional, Shah, P. S., additional, Vanikar, A. V., additional, Modi, P. R., additional, Shah, P. R., additional, Gumber, M. R., additional, Patel, H. V., additional, Engineer, D. P., additional, Shah, V. R., additional, Rizvi, J., additional, Trivedi, H. L., additional, Malheiro, J., additional, Dias, L., additional, Martins, L. S., additional, Fonseca, I., additional, Pedroso, S., additional, Almeida, M., additional, Castro-Henriques, A., additional, Cabrita, A., additional, Costa, C., additional, Ritta, M., additional, Sinesi, F., additional, Sidoti, F., additional, Mantovani, S., additional, Di Nauta, A., additional, Messina, M., additional, Cavallo, R., additional, Verflova, A., additional, Svobodova, E., additional, Slatinska, J., additional, Slavcev, A., additional, Pokorna, E., additional, Viklicky, O., additional, Yagan, J., additional, Chandraker, A., additional, Diena, D., additional, Tognarelli, G., additional, Ranghino, A., additional, Bussolino, S., additional, Fop, F., additional, Segoloni, G. P., additional, Biancone, L., additional, Leone, F., additional, Mauro, M. V., additional, Gigliotti, P., additional, Lofaro, D., additional, Greco, F., additional, Perugini, D., additional, Papalia, T., additional, Perri, A., additional, Vizza, D., additional, Giraldi, C., additional, Bonofilgio, R., additional, Luis-Lima, S., additional, Marrero, D., additional, Gonzalez-Rinne, A., additional, Torres, A., additional, Salido, E., additional, Jimenez-Sosa, A., additional, Aldea-Perona, A., additional, Gonzalez-Posada, J. M., additional, Perez-Tamajon, L., additional, Rodriguez-Hernandez, A., additional, Negrin-Mena, N., additional, Porrini, E., additional, Pihlstrom, H., additional, Dahle, D. O., additional, Holdaas, H., additional, Von Der Lippe, N., additional, Waldum, B., additional, Brekke, F., additional, Amro, A., additional, Os, I., additional, Klin, P., additional, Sanabria, H., additional, Bridoux, P., additional, De Francesco, J., additional, Fortunato, R. M., additional, Raffaele, P., additional, Kong, J., additional, Son, S. H., additional, Kwon, H. Y., additional, Whang, E. J., additional, Choi, W. Y., additional, Yoon, C. S., additional, Thanaraj, V., additional, Theakstone, A., additional, Stopper, K., additional, Ferraro, A., additional, Bhattacharjya, S., additional, Devonald, M., additional, Williams, A., additional, Mella, A., additional, Gallo, E., additional, Di Vico, M. C., additional, Pagani, F., additional, Gai, M., additional, Cho, H. J., additional, Nho, K. W., additional, Park, S.-K., additional, Kim, S. B., additional, Yoshida, K., additional, Ishii, D., additional, Ohyama, T., additional, Kohguchi, D., additional, Takeuchi, Y., additional, Varga, A., additional, Sandor, B., additional, Kalmar-Nagy, K., additional, Toth, A., additional, Toth, K., additional, Szakaly, P., additional, Kildushevsky, A., additional, Fedulkina, V., additional, Kantaria, R., additional, Staeck, O., additional, Halleck, F., additional, Rissling, O., additional, Naik, M., additional, Neumayer, H.-H., additional, Budde, K., additional, Khadzhynov, D., additional, Bhadauria, D., additional, Kaul, A., additional, Prasad, N., additional, Sharma, R. K., additional, Sezer, S., additional, Bal, Z., additional, Erkmen Uyar, M., additional, Guliyev, O., additional, Erdemir, B., additional, Colak, T., additional, Ozdemir, N., additional, Haberal, M., additional, Caliskan, Y., additional, Yazici, H., additional, Artan, A. S., additional, Oto, O. A., additional, Aysuna, N., additional, Bozfakioglu, S., additional, Turkmen, A., additional, Yildiz, A., additional, Sever, M. S., additional, Yagisawa, T., additional, Nukui, A., additional, Kimura, T., additional, Nannmoku, K., additional, Kurosawa, A., additional, Sakuma, Y., additional, Miki, A., additional, Damiano, F., additional, Ligabue, G., additional, De Biasi, S., additional, Granito, M., additional, Cossarizza, A., additional, Cappelli, G., additional, Henriques, A. C., additional, Davide, J., additional, Von During, M. E., additional, Jenssen, T. G., additional, Bollerslev, J., additional, Godang, K., additional, Asberg, A., additional, Bachelet, T., additional, Martinez, C., additional, Bello, A., additional, Kejji, S., additional, Couzi, L., additional, Guidicelli, G., additional, Lepreux, S., additional, Visentin, J., additional, Congy-Jolivet, N., additional, Rostaing, L., additional, Taupin, J.-L., additional, Kamar, N., additional, Merville, P., additional, Ozdemir, H., additional, Yildirim, S., additional, Tutal, E., additional, Sayin, B., additional, Ozdemir Acar, N., additional, Banasik, M., additional, Boratynska, M., additional, Koscielska-Kasprzak, K., additional, Kaminska, D., additional, Bartoszek, D., additional, Mazanowska, O., additional, Krajewska, M., additional, Zmonarski, S., additional, Chudoba, P., additional, Dawiskiba, T., additional, Protasiewicz, M., additional, Halon, A., additional, Sas, A., additional, Kaminska, M., additional, Klinger, M., additional, Stefanovic, N., additional, Cvetkovic, T., additional, Velickovic - Radovanovic, R., additional, Jevtovic - Stoimenov, T., additional, Vlahovic, P., additional, Rungta, R., additional, Das, P., additional, Ray, D. S., additional, Gupta, S., additional, Kolonko, A., additional, Szotowska, M., additional, Kuczera, P., additional, Chudek, J., additional, Wiecek, A., additional, Sikora-Grabka, E., additional, Adamczak, M., additional, Madej, P., additional, Amanova, A., additional, Kendi Celebi, Z., additional, Bakar, F., additional, Caglayan, M. G., additional, Keven, K., additional, Massimetti, C., additional, Imperato, G., additional, Zampi, G., additional, De Vincenzi, A., additional, Fabbri, G. D. D., additional, Brescia, F., additional, Feriozzi, S., additional, Filipov, J. J., additional, Zlatkov, B. K., additional, Dimitrov, E. P., additional, Svinarov, D. A., additional, Poesen, R., additional, De Vusser, K., additional, Evenepoel, P., additional, Kuypers, D., additional, Naesens, M., additional, Meijers, B., additional, Kocak, H., additional, Yilmaz, V. T., additional, Yilmaz, F., additional, Uslu, H. B., additional, Aliosmanoglu, I., additional, Ermis, H., additional, Dinckan, A., additional, Cetinkaya, R., additional, Ersoy, F. F., additional, Suleymanlar, G., additional, Oliveira, J.-C., additional, Santos, J., additional, Lobato, L., additional, Mendonca, D., additional, Watarai, Y., additional, Yamamoto, T., additional, Tsujita, M., additional, Hiramitsu, T., additional, Goto, N., additional, Narumi, S., additional, Kobayashi, T., additional, Line, P.-D., additional, Housawi, A., additional, House, A., additional, Ng, C., additional, Denesyk, K., additional, Rehman, F., additional, Moist, L., additional, Musetti, C., additional, Battista, M., additional, Izzo, C., additional, Guglielmetti, G., additional, Airoldi, A., additional, Stratta, P., additional, Cena, T., additional, Quaglia, M., additional, Fenoglio, R., additional, Cagna, D., additional, Amoroso, A., additional, Palmisano, A., additional, Degli Antoni, A. M., additional, Vaglio, A., additional, Piotti, G., additional, Cremaschi, E., additional, Buzio, C., additional, Maggiore, U., additional, Lee, M.-C., additional, Hsu, B.-G., additional, Zalamea Jarrin, F., additional, Sanchez Sobrino, B., additional, Lafuente Covarrubias, O., additional, Karsten Alvarez, S., additional, Dominguez Apinaniz, P., additional, Llopez Carratala, R., additional, Portoles Perez, J., additional, Yildirim, T., additional, Yilmaz, R., additional, Turkmen, E., additional, Altindal, M., additional, Arici, M., additional, Altun, B., additional, Erdem, Y., additional, Dounousi, E., additional, Mitsis, M., additional, Naka, K., additional, Pappas, H., additional, Lakkas, L., additional, Harisis, H., additional, Pappas, K., additional, Koutlas, V., additional, Tzalavra, I., additional, Spanos, G., additional, Michalis, L., additional, Siamopoulos, K., additional, Iwabuchi, T., additional, Nanmoku, K., additional, Yasunaru, S., additional, Yoshikawa, M., additional, Kitamura, K., additional, Fuji, H., additional, Fujisawa, M., additional, Nishi, S., additional, Carta, P., additional, Zanazzi, M., additional, Buti, E., additional, Larti, A., additional, Caroti, L., additional, Di Maria, L., additional, Minetti, E. E., additional, Shi, Y., additional, Luo, L., additional, Cai, B., additional, Wang, T., additional, Zou, Y., additional, Wang, L., additional, Kim, Y., additional, Kim, H. S., additional, Choi, B. S., additional, Park, C. W., additional, Yang, C. W., additional, Kim, Y.-S., additional, Chung, B. H., additional, Baek, C. H., additional, Kim, M., additional, Kim, J.-S., additional, Yang, W. S., additional, Han, D. J., additional, Mikolasevic, I., additional, Racki, S., additional, Lukenda, V., additional, Persic, M. P., additional, Colic, M., additional, Devcic, B., additional, Orlic, L., additional, Gurlek Demirci, B., additional, Say N, C. B., additional, Ozdemir Acar, F. N., additional, Vali, S., additional, Ismal, K., additional, Sahay, M., additional, Civiletti, F., additional, Cantaluppi, V., additional, Medica, D., additional, Mazzeo, A. T., additional, Assenzio, B., additional, Mastromauro, I., additional, Deambrosis, I., additional, Giaretta, F., additional, Fanelli, V., additional, Mascia, L., additional, Gkirdis, I., additional, Bechlioulis, A., additional, Evangelou, D., additional, Zarzoulas, F., additional, Kotsia, A., additional, Balafa, O., additional, Tzeltzes, G., additional, Nakas, G., additional, Kalaitzidis, R., additional, Katsouras, C., additional, Uyanik, S., additional, Toprak, S. K., additional, Ilhan, O., additional, Ekmen Uyar, M., additional, Hernandez Vargas, H., additional, Artamendi Larranaga, M., additional, Ramalle Gomara, E., additional, Gil Catalinas, F., additional, Bello Ovalle, A., additional, Pimentel Guzman, G., additional, Coloma Lopez, A., additional, Sierra Carpio, M., additional, Gil Paraiso, A., additional, Dall Anesse, C., additional, Beired Val, I., additional, Huarte Loza, E., additional, Choy, B. Y., additional, Kwan, L., additional, Mok, M., additional, Chan, T. M., additional, Yamakawa, T., additional, Kobayashi, A., additional, Yamamoto, I., additional, Mafune, A., additional, Nakada, Y., additional, Tannno, Y., additional, Tsuboi, N., additional, Yamamoto, H., additional, Yokoyama, K., additional, Ohkido, I., additional, Yokoo, T., additional, Luque, Y., additional, Anglicheau, D., additional, Rabant, M., additional, Clement, R., additional, Kreis, H., additional, Sartorius, A., additional, Noel, L.-H., additional, Timsit, M.-O., additional, Legendre, C., additional, Rancic, N., additional, Vavic, N., additional, Dragojevic-Simic, V., additional, Katic, J., additional, Jacimovic, N., additional, Kovacevic, A., additional, Mikov, M., additional, Veldhuijzen, N. M. H., additional, Rookmaaker, M. B., additional, Van Zuilen, A. D., additional, Nquyen, T. Q., additional, Boer, W. H., additional, Sahtout, W., additional, Ghezaiel, H., additional, Azzebi, A., additional, Ben Abdelkrim, S., additional, Guedri, Y., additional, Mrabet, S., additional, Nouira, S., additional, Ferdaws, S., additional, Amor, S., additional, Belarbia, A., additional, Zellama, D., additional, Mokni, M., additional, Achour, A., additional, Parikova, A., additional, Hanzal, V., additional, Fronek, J., additional, Orandi, B. J., additional, James, N. T., additional, Montgomery, R. A., additional, Desai, N. M., additional, Segev, D. L., additional, Fontana, F., additional, Ballestri, M., additional, and Magistroni, R., additional
- Published
- 2014
- Full Text
- View/download PDF
6. INCREASED SERUM FERRITIN LEVELS IN ACTIVE BEHÇET'S DISEASE
- Author
-
Odabas, A. R., Karakuzu, A., Cetinkaya, R., Selcuk, Y., Mevlut sait keles, and Bilen, H.
- Subjects
General Medicine - Published
- 2002
- Full Text
- View/download PDF
7. Evaluation of dihydropteridine reductase activities in patients with kidney failure
- Author
-
Palabıyık Şaziye Sezin, Aşçı Ali, Girgin Gözde, Şahin Gönül, Çetinkaya Ramazan, and Baydar Terken
- Subjects
biopterin ,dihydropteridine reductase ,hemodialysis ,tetrahydrobiopterin ,Crystallography ,QD901-999 - Abstract
End-stage renal disease (ESRD) is the inability of the kidneys to remove waste products from the blood. The most important factors causing ESRD that require hemodialysis are diabetes and hypertension. There are limited numbers of studies to evaluate tetrahydrobiopterin pathway in these patients. The aim of the study was to evaluate tetrahydrobiopterin pathway by measuring its important components, biopterin to creatinine concentrations and dihydropteridine reductase activities in diabetes and hypertension patients treated with/without hemodialysis. The patients undergoing hemodialysis were classified as diabetic nephropathy (n=21), hypertensive nephropathy (n=20) and others (n=30), while the controls consisted of healthy subjects (n=21), diabetic subjects (n=23) and hypertensive subjects (n=22) without any renal disorder. It was found that urinary biopterin to creatinine concentrations significantly increased in kidney failure patients undergoing hemodialysis compared to the healthy control group (p
- Published
- 2013
- Full Text
- View/download PDF
8. Bullous pemphigoid on an incision scar of total knee prosthesis
- Author
-
Kavak Ayse, Parlak Ali, Çetinkaya Reyhan, and Tüzüner Tolga
- Subjects
Dermatology ,RL1-803 - Published
- 2006
9. Tranexamic-acid-induced acute renal cortical necrosis in a patient with haemophilia A.
- Author
-
Odabaş, A R, Cetinkaya, R, Selçuk, Y, Kaya, H, and Coşkun, U
- Published
- 2001
- Full Text
- View/download PDF
10. Mesalazine induced focal segmental glomerulosclerosis in a patient with ulcerative colitis.
- Author
-
Yilmaz F, Uslu B, Akkaya B, and Cetinkaya R
- Subjects
- Adult, Angiotensin II Type 1 Receptor Blockers therapeutic use, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Colitis, Ulcerative diagnosis, Glomerulosclerosis, Focal Segmental diagnosis, Glomerulosclerosis, Focal Segmental drug therapy, Glucocorticoids therapeutic use, Humans, Kidney pathology, Male, Nephrotic Syndrome diagnosis, Nephrotic Syndrome drug therapy, Treatment Outcome, Anti-Inflammatory Agents, Non-Steroidal adverse effects, Colitis, Ulcerative drug therapy, Glomerulosclerosis, Focal Segmental chemically induced, Kidney drug effects, Mesalamine adverse effects, Nephrotic Syndrome chemically induced
- Abstract
Focal segmental glomerulosclerosis (FSGS) and other glomerulonephritis due to the use of 5-aminosalicylic acid derivatives have been reported in the literature. A 38-year-old male who had been using mesalazine for four years because of ulcerative colitis applied to doctor due to swelling in the lower extremities. The patient was diagnosed with nephrotic syndrome (NS). Renal biopsy was performed, and FSGS was diagnosed. Antiproteinuric treatments were initiated with steroid therapy. The patient has been followed with the normal renal function of the after treatment. 5-aminosalicylic acid derivatives affect renal functions at different levels and caused in NS., Competing Interests: None
- Published
- 2020
- Full Text
- View/download PDF
11. Sexual Dysfunction Is Associated with Depression and Anxiety in Patients with Predialytic Chronic Kidney Disease.
- Author
-
Guven S, Sari F, Inci A, and Cetinkaya R
- Abstract
Objective: We aimed to determine the prevalence of sexual dysfunction and clarify the relationship between sexual dysfunction and depressive mood state, drugs, and disease activities in patients with predialytic chronic kidney disease (CKD)., Materials and Methods: In total, 150 patients with CKD who had an estimated glomerular filtration rate of 15-60 mL/min were included; 65 healthy controls were selected. A detailed medical and sexual medical history was taken from individuals in the control and patient groups by applying the Golombok-Rust Inventory of Sexual Satisfaction and Hospital Anxiety and Depression Scale., Results: Sexual frequency (p=0.027), impotence (p<0.001), and premature ejaculation scores (p<0.001) in male patients and sexual frequency (p=0.004), communication (p=0.004),, satisfaction (p<0.001), avoidance (p=0.008), orgasmic dysfunction (p<0.001), sensuality (p=0.002), and total sexual dysfunction scores (p<0.001) in female patients with CKD were found to be higher compared with the control group. In female patients, the depression scores of patients with stage 3 CKD were found to be higher than those of patients with stage 4 CKD (p=0.028). The avoidance scores of male patients with depression (p=0.006) were high. In contrast, the communication score of female patients with depression was high (p=0.004). It has been detected that the factors that affect the sexual dysfunction score of patients with CKD in males are age (p=0.006), hypertension (p=0.008), anxiety (p=0.003), and depression (p=0.002) and those in female patients are age (p=0.034), anxiety (p<0.001), and depression (p=0.001)., Conclusion: Patients with predialytic CKD substantially have sexual dysfunction. The most important factors that affect sexual dysfunction are age, hypertension, anxiety, and depression., Competing Interests: Conflict of Interest: Authors have no conflict of interest to declare.
- Published
- 2018
- Full Text
- View/download PDF
12. MR Tractography in Short Lasting Unilateral Neuralgiform Headache Attacks with Conjunctival Injection and Tearing (SUNCT) Patients: Case Reports.
- Author
-
Coskun O, Ucar M, Vuralli D, Yildirim F, Cetinkaya R, Akin Takmaz S, and Ucler S
- Subjects
- Aged, Cluster Headache complications, Conjunctiva, Female, Humans, Middle Aged, Tears, Trigeminal Neuralgia complications, Cluster Headache diagnostic imaging, Diffusion Tensor Imaging methods, Magnetic Resonance Imaging methods, Trigeminal Neuralgia diagnostic imaging
- Abstract
Background: Short-lasting unilateral neuralgiform headache attack with conjunctival injection and tearing (SUNCT) is one of the trigeminal autonomic cephalalgias where neurovascular compression was detected in neuroimaging in recent years., Case: We report two cases, a 52-year-old adult and a 69-year-old elderly patient with short-lasting and recurrent headache combined with cranial autonomic features. Diffusion tensor imaging (DTI) and magnetic resonance (MR) tractography of both patients outlined structural changes of the trigeminal nerve revealing neurovascular compression. Pain and autonomic symptoms were completely relieved in the 52-year-old patient who underwent microvascular decompression surgery., Conclusion: To our knowledge, this is the first time in the literature where MR tractography revealed structural changes in the trigeminal nerve secondary to neurovascular compression in SUNCT patients. We suggest that in SUNCT patients high-resolution magnetic resonance imaging (MRI) and/or DTI-MR tractography should be performed to exclude neurovascular compression. We propose that the compression of the trigeminal nerve could generate SUNCT symptoms and the posterior hypothalamus could be activated secondarily. With this point of view, trigeminal neuralgia and SUNCT could represent the different features of the neurovascular compression spectrum., (© 2017 American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com)
- Published
- 2017
- Full Text
- View/download PDF
13. The effects of dual and triple combinations of trandolapril, telmisartan, and verapamil on overt proteinuria in the patients with diabetic nephropathy.
- Author
-
Albayrak B, Cankaya E, Cetinkaya R, Cerrah S, and Bilen Y
- Subjects
- Adolescent, Adult, Aged, Blood Pressure, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Telmisartan, Young Adult, Angiotensin-Converting Enzyme Inhibitors administration & dosage, Angiotensin-Converting Enzyme Inhibitors therapeutic use, Benzimidazoles administration & dosage, Benzimidazoles therapeutic use, Benzoates administration & dosage, Benzoates therapeutic use, Diabetic Nephropathies drug therapy, Indoles administration & dosage, Indoles therapeutic use, Proteinuria drug therapy, Verapamil administration & dosage, Verapamil therapeutic use
- Abstract
Diabetic nephropathy (DN) is one of the most important causes of the end-stage renal failure and its prevalence is found to be increasing. The presence of hypertension and progressive proteinuria is among the important findings. In this study, the effects of double and triple combinations of trandolapril, telmisartan, and verapamil on proteinuria were investigated in diabetic patients with nephropathy. Seventy-eight patients (mean age: 56.11 ± 11.26 years; 47 females and 31 males) with overt proteinuria and DN were included in this study. The patients were divided into four groups: Group I (n: 18, trandolapril + telmisartan), Group II (n: 20, trandolapril + verapamil), Group III (n: 20, trandolapril +telmisartan + verapamil), and Group IV (n: 20, telmisartan + verapamil). At the end of a three-month therapy, within and between group comparisons were done about the effects of the use of double or triple drug combinations on proteinuria, glomerular filtration rate (GFR), electrolytes, serum albumin, low-density lipoprotein (LDL)- cholesterol, and HbA1C. There was no significant difference among groups in terms of age, gender, diabetes duration, body mass index, and retinopathy frequency. The decreases in proteinuria and mean arterial blood pressure (MABP) were significant in all groups. The decrease in proteinuria was independent of the decrease in MABP [the reduction rate in proteinuria was 39% (P <0.001) in Group I, 37% (P <0.001) in Group II, 42% (P <0.001) in Group III, and 43% (P <0.001) in Group IV; the reduction rate in MABP was 10.6% (P <0.001) in Group I, 13.7% (P <0.001) in Group II, 17.5% (P <0.001) in Group III, and 15.4% (P <0.001) in Group IV]. Decrease in HbA1C (before and after treatment) was significant in Groups III and IV when com- pared to Groups I and II. Any adverse event, like hyperkalemia, was not observed. There was no significant difference among the groups in terms of GFR, LDL-cholesterol, albumin, and potassium. All the patients tolerated the drugs well. In conclusion, in patients with DN, both double or triple combinations of trandolapril, telmisartan and verapamil resulted in significant decreases in proteinuria and MABP. Triple combinations did not have any superiority over double combinations. Therefore, the suitable drug combinations may be chosen according to the clinical status of a patient.
- Published
- 2016
- Full Text
- View/download PDF
14. New-Onset Diabetes Mellitus Associated with Sirolimus Use in Renal Transplant Recipients.
- Author
-
Yilmaz VT, Kocak H, Dinckan A, and Cetinkaya R
- Abstract
New-onset diabetes after transplantation and impaired glucose tolerance are very common in renal transplant patients. New-onset diabetes after transplantation (NODAT) is associated with increased cardiovascular morbidity and mortality, reduced graft and patient survival. Several risk factors for NODAT have been identified: age, obesity, family history of diabetes mellitus and HCV infection. In addition, steroid and calcineurin inhibitors also contribute to the development of NODAT. Sirolimus causes immunosuppressive effects by inhibiting mammalian target of rapamycin (mTOR), and has well known side effects. The effects of sirolimus on glucose metabolism and contribution to NODAT development are not clearly known. In this report, we presented five RTX patients who developed NODAT under the treatment of sirolimus.
- Published
- 2015
- Full Text
- View/download PDF
15. Assessment of Long-Term Outcomes in Hbs Ag-Negative Renal Transplant Recipients Transplanted from Hbs Ag-Positive Donors.
- Author
-
Yilmaz VT, Ulger BV, Aliosmanoglu İ, Erbis H, Tuna Y, Akbas H, Ozdem S, Cetinkaya R, Suleymanlar G, and Kocak H
- Subjects
- Female, Follow-Up Studies, Hepatitis B epidemiology, Humans, Incidence, Male, Prognosis, Retrospective Studies, Treatment Outcome, Graft Rejection immunology, Graft Survival immunology, Hepatitis B Antibodies, Hepatitis B Surface Antigens analysis, Kidney Transplantation methods, Tissue Donors, Transplant Recipients
- Abstract
Background: The aim of this study was to evaluate the long-term outcomes of renal transplantation from Hbs Ag-positive donors to Hbs Ag-negative recipients., Material and Methods: A total of 78 patients who underwent renal transplantation in our clinic between January 2006 and May 2014 were included in the study. Patients were divided into 2 groups: Group 1: Donor Hbs Ag (+) (n=26, Hbs Ab (-), Hbe Ag (-), Hbe Ab (+), Hbc Ig total (+) and HBV DNA (+), male/female (M/F): 16 (61.5%)/10 (38.5%), and Group 2: Donor Hbs Ag (-) (n=52, M/F: 41 (78.8%)/11 (21.2%). Hbs Ab levels were similar in recipients in both groups. Data were collected retrospectively. Analyses were performed by using SPSS 20.0 software, and patient and graft survival were measured by using Kaplan-Meier survival curve and compared by using the log-rank test., Results: Demographic data were similar in the 2 groups. The rate of acute Hepatitis B infection was significantly higher in Group 1 than in Group 2 [n=3 (11.5%) vs. n=0 (0%), respectively, p=0.012]. Acute hepatitis B attacks were detected in vaccinated patients. Graft survival rates (groups 1 and 2, respectively; at 1st, 3rd, 5th and 8th years: 95% vs. 96%, 95% vs. 94%, 85% vs. 88%, 85% vs. 82%, p=0.970) and patient survival rates (p=0.098), acute rejection rates (p=0.725), delayed graft function, chronic allograft dysfunction, new-onset diabetes after transplantation (NODAT), cytomegalovirus infection, and the need for postoperative dialysis and plasmapheresis were similar between groups., Conclusions: Our study revealed that the risk of developing acute hepatitis B was higher in patients renally transplanted from Hbs Ag (+) donors, but the other clinical outcomes were similar between groups.
- Published
- 2015
- Full Text
- View/download PDF
16. FGF-23, α-Klotho Gene Polymorphism and Their Relationship with the Markers of Bone Metabolism in Chronic Peritoneal Dialysis Patients.
- Author
-
Yilmaz VT, Ozdem S, Donmez L, Cetinkaya R, Suleymanlar G, and Ersoy FF
- Abstract
Objective: The aim of the present study was to evaluate the variations of some major bone metabolism markers with reference to klotho gene polymorphism (KGP) and bone mineral density (BMD) values in patients on chronic peritoneal dialysis (CPD)., Materials and Methods: In 51 CPD patients and 40 healthy persons, assays for intact parathormone (iPTH), fibroblast growth factor 23 (FGF-23), osteoprotegerin (OPG), osteocalcin (OC), procollagen type-1 N terminal propeptide (PINP), beta- crosslaps (beta CTx), tartrate resistant acid phosphatase (TRAP5b), bone alkaline phosphatase (BAP), 1,25(OH)D3, and 25(OH)D3 and α-klotho gene mutations were performed., Results: In CPD patients, 1,25(OH)D3 and 25(OH)D3 deficiency rates were 96% and 94% respectively. iPTH (249 pg/mL vs 39 pg/mL) and FGF-23 (1089 RU/mL vs 153 RU/mL), OPG, OC, PINP, beta CTx, TRAP5b levels were significantly higher in patients. iPTH levels and whole-body BMD values were negatively correlated in patients. The rate of KGP was similar in all groups., Conclusion: In CPD patients, besides vitamin D deficiency, high levels of OPG, OC, PINP, beta CTx, TRAP5b were evident. Positive correlation between iPTH levels and BAP and PINP levels suggested a diagnostic value for those markers during the management of CKD MBD. On the other hand, high serum TRAP5b concentrations did not seem to be affected by neither calcitriol treatment nor the severity of hyperparathyroidism. iPTH and FGF-23 levels and whole-body BMD values showed a significant negative correlation. We were unable to show any correlation between KGP and any of the CKD-MBD parameters measured in this study.
- Published
- 2015
- Full Text
- View/download PDF
17. Significant Association between Serum Levels of Von Willebrand Factor (vWF) Antigen with Stages of Cirrhosis.
- Author
-
Yilmaz VT, Dincer D, Avci AB, and Cetinkaya R
- Abstract
Objective: Von Willebrand factor (vWF) is a mediator that increases endotoxemic medium like in cirrhosis. In this study we evaluated the association of serum VWF antigen (Ag) level with the stage of cirrhosis (according to Child-Pugh classification)., Materials and Methods: We included 82 cirrhotic patients (Female/Male (F/M): 26/56) and 86 healthy subjects (F/M: 44/42) in the study. Ages of the both groups of patients were not different (P= 0.095). We excluded possible other reasons that may cause VWF level increase. Diagnosis of cirrhosis was made on the basis of biopsy in 7 patients and with clinical and laboratory parameters in 75 patients. VWF Ag level was determined by immunoturbidimetric test. The stage of cirrhosis was defined with Child-Pugh classification. Data were analysed by using Statistical Package for the Social Sciences (SPSS) 10.0 software program., Results: VWF Ag level was significantly higher in cirrhotic patients compared to control group (220±90 and 87±38, P<0.001, respectively). We observed significant increase of VWF Ag level with the increasing stages of cirrhosis according to Child-Pugh score (VWF Ag level for Child A-B-C 156.4±54/215±45/284.8±93, respectively; P values for Child A-B/A-C/B-C; <0.001/<0.001/0.006, respectively)., Conclusion: Serum VWF Ag level increases in cirrhotic patients and this is more pronounced with higher stages of cirrhosis.
- Published
- 2015
- Full Text
- View/download PDF
18. Treatment Results of Patients With Lupus Nephritis: A Single Center's Experience.
- Author
-
Gunes C, Keles M, Uyanik A, Cetinkaya R, and Sari RA
- Abstract
Objective: Lupus nephritis (LN) is a type of organ involvement of systemic lupus erythematosus (SLE) that leads to disease-related morbidity and mortality. Lack of good treatments for LN continues to be problematic. Many different treatment protocols are applied in treatment centers. Not every treatment protocol is successful. Moreover, patients who reached remission may present with exacerbations. In this study, we aimed to evaluate the treatment results of our patients and investigate their remission rates as well as factors that affect remissions., Materials and Methods: We retrospectively investigated the results of 41 patients who were diagnosed with lupus nephritis after kidney biopsy in the Nephrology and Immunology-Rheumatology departments of Atatürk University Medical Faculty Training Hospital between January 2000 and December 2008. Demographic information, clinical history and laboratory results were collected from each patient's records. The relationships among clinical, laboratory, demographic parameters and remissions were investigated. The patients were grouped in terms of urine protein levels; patients with urine protein < 330 mg/day were regarded as in remission and patients with urine protein ≥ 330 mg/day were were regarded as uncontrolled., Results: At the end of a 12-month period of therapy, 24 (58.5 %) of the patients were in remission. There were no statistically significant relationships among age, sex, anti-ds-DNA, C3, C4, activity indexes, chronicity indexes, serum level of creatinine, urine protein levels and remission (p>0.05). We compared class 3 LN patients at the 6th and 12th months according to treatment protocols. Azathioprin or mycophenolate mophetil were significantly better at placing urine protein levels in remission as compared to cyclophosphamide (p<0.05)., Conclusion: According to our study, no relationship was found between basal clinical and laboratory parameters and patient remission. Response rates of our LN patients were similar to those in the literature. However, complete remission is still a problem in LN. The results of the protocols used in the treatment of LN show similarities. Although there are some data suggesting that MMF used in recent years is effective, it should be supported by prospective multicenter studies. It is important to note that it is difficult to achieve complete remission in LN patients.
- Published
- 2010
- Full Text
- View/download PDF
19. Neutropenia related to valacyclovir and valganciclovir in 2 renal transplant patients and treatment with granulocyte colony stimulating factor: a case report.
- Author
-
Keles M, Yildirim R, Uyanik A, Turkmen M, Bilen Y, Aydinli B, Cetinkaya R, and Polat KY
- Subjects
- Acyclovir adverse effects, Adolescent, Adult, Cytomegalovirus Infections etiology, Filgrastim, Ganciclovir adverse effects, Humans, Male, Neutropenia chemically induced, Recombinant Proteins, Treatment Outcome, Valacyclovir, Valganciclovir, Valine adverse effects, Acyclovir analogs & derivatives, Antiviral Agents adverse effects, Cytomegalovirus Infections prevention & control, Ganciclovir analogs & derivatives, Granulocyte Colony-Stimulating Factor therapeutic use, Kidney Transplantation adverse effects, Neutropenia drug therapy, Valine analogs & derivatives
- Abstract
Objectives: Posttransplant leukopenia is frequently observed in renal transplant. Granulocyte colony-stimulating factor controls the production of functional neutrophils and their release into peripheral blood. Granulocyte colony-stimulating factor has been widely and frequently used for many conditions and disorders in the field of hematology and oncology., Materials and Methods: We present the cases of valacyclovir-related and valganciclovir-related neutropenia in 2 renal transplant recipients., Results: Both cases had renal transplants from live donors. The first one was an 18-year-old man. Laboratory investigations revealed his leukocyte count as 1.7 x 10(9)/L. The patient was using mycophenolate mofetil, cyclosporine, and valganciclovir. Mycophenolate mofetil was stopped because he had neutropenia, and later, valganciclovir was also stopped because the neutropenia persisted. Because the neutropenia did not recover after we discontinued valganciclovir, the patient was administered granulocyte colony-stimulating factor. The neutrophil count increased to 2.2 x 10(9)/L (leucocyte count to 6.5 x 10(9)/L) after 24 hours. The second case was a 37-year-old man and was using mycophenolic acid, tacrolimus, and valacyclovir. Laboratory investigations revealed his leukocyte count to be 1.3 x 10(9)/L. Mycophenolic acid and valganciclovir were stopped owing to neutropenia. The patient was administered granulocyte colony-stimulating factor, and the neutrophil count increased to 3.8 x 10(9)/L (leucocyte count to 5.8 x 10(9)/L). The kidney functions did not deteriorate in either patient, and the patients' kidney functions were similar to baseline levels 12 months after surgery., Conclusions: We conclude that granulocyte colony-stimulating factor can be used safely and effectively in renal transplant patients.
- Published
- 2010
20. The frequency of familial mediterranean Fever related amyloidosis in renal waiting list for transplantation.
- Author
-
Keles M, Eyerci N, Uyanik A, Aydinli B, Sahin GZ, Cetinkaya R, Pirim I, and Polat KY
- Abstract
Objective: Our goal is to investigate the distribution of MEFV mutations in patients with renal amyloidosis who are in renal transplant waiting list which is prepared for transplantation., Materials and Methods: FMF was diagnosed in 25 of the 297 patients between the years 2004 and 2008, who were involved in the study (15 male, 10 female; age 34±7.8). 5 out of 25 patients were transplanted, remaining were waiting for Tx. Biopsy results were amyloidosis and taken from renal (n:16), rectal (n:8) and duodenal (1).All of them were carrier of mutations in both pyrin alleles.The primer cause of chronic renal failure in our group was secondary AA amyloidosis. DNA was isolated from 25 whole blood samples. The NanoChip Molecular Biology Workstation (Nanogen) uses electronic microarrays for mutation detection. Exon 2,3,5 and 10 of pyrin gene genotypes were identified in the NanoChip., Results: Genetic analysis of the patients demonstrated that each subject carries either homozygote or compound heterozygote mutations of the gene. The most common mutations were M694V, V726A, E148Q and M680I., Conclusions: The clinic manifestation and complain of our patients were febrile and painful attacks such as in the abdomen, chest and joints due to inflammation of the peritoneum, pleura and synovial membrane. The major problem in FMF is the occurrence of amyloidosis that primarily affects the kidneys causing proteinuria and renal failure. Dialysis and renal transplantation can be treatment, but it is important to diagnose FMF at earliest stages. The percentage of FMF patients in our waiting list was 8.4%. Moreover, in our region FMF incidence is highly frequent, so FMF should be chased by genetically so as to prevent chronic renal failure due to amyloidosis.
- Published
- 2010
- Full Text
- View/download PDF
21. Salivary gland function in continuous ambulatory peritoneal dialysis patients by 99mTc-pertechnetate scintigraphy.
- Author
-
Keles M, Seven B, Varoglu E, Uyanik A, Cayir K, Kursad Ayan A, Emre H, and Cetinkaya R
- Subjects
- Adult, Aged, Female, Humans, Male, Middle Aged, Radionuclide Imaging, Radiopharmaceuticals, Reproducibility of Results, Sensitivity and Specificity, Young Adult, Peritoneal Dialysis, Continuous Ambulatory adverse effects, Salivary Glands diagnostic imaging, Sodium Pertechnetate Tc 99m, Xerostomia diagnostic imaging, Xerostomia etiology
- Abstract
The purpose of this study was to evaluate the alterations in salivary gland function in patients who receiving continuous ambulatory peritoneal dialysis (CAPD) for chronic renal failure (CRF) using technetium-99m pertechnetate ((99m)Tc-P) salivary gland scintigraphy. The study population consisted of 36 CAPD patients (16 males and 20 females, ranging in age from 19 to 73 years, mean age 44.94+/-15.01 years) and 20 healthy controls (11 males and 9 females, ranging in age from 31 to 51 years, mean age 41.25+/-5.62 years). All patients and healthy controls underwent salivary gland scintigraphy. After the intravenous administration of 185MBq of (99m)Tc-P, dynamic salivary gland scintigraphy was performed for 25min. On the basis of the time-activity curves, the following glandular function parameters were calculated for the parotid and submandibular salivary glands: uptake ratio, maximum accumulation, and ejection fraction. Our results showed: All functional parameters obtained for CAPD patients were significantly lower than for healthy controls (P<0.05). In conclusion, this study demonstrated that salivary gland function, an important determinant of oral health, is impaired among the CRF patients treated with CAPD compared with healthy controls, as evaluated by (99m)Tc-P salivary gland scintigraphy.
- Published
- 2010
22. Fenofibrate monotherapy-induced rhabdomyolysis in a patient with type-2 diabetes.
- Author
-
Cetinkaya R, Uyanik A, Yildirim R, Bilen Y, and Keles M
- Subjects
- Female, Humans, Hydrotherapy, Hyperlipidemias drug therapy, Middle Aged, Risk Factors, Diabetes Mellitus, Type 2 complications, Fenofibrate adverse effects, Hypolipidemic Agents adverse effects, Rhabdomyolysis chemically induced
- Published
- 2008
23. AA amyloidosis complicating an inflammatory abdominal aortic aneurysm.
- Author
-
Odabas AR, Cetinkaya R, Selcuk Y, Gundogdu C, Onuk MD, Ozbey I, and Coskun U
- Subjects
- Amyloidosis diagnostic imaging, Aortitis diagnostic imaging, Humans, Male, Middle Aged, Tomography, X-Ray Computed, Amyloidosis complications, Aorta, Abdominal diagnostic imaging, Aortic Aneurysm complications, Aortitis complications
- Published
- 2002
- Full Text
- View/download PDF
24. Thyroid abnormalities in lithium-treated patients with bipolar affective disorder.
- Author
-
Cayköylü A, Capoğlu I, Unüvar N, Erdem F, and Cetinkaya R
- Subjects
- Adolescent, Adult, Bipolar Disorder blood, Female, Goiter blood, Goiter chemically induced, Humans, Hyperthyroidism blood, Hyperthyroidism chemically induced, Hypothyroidism blood, Hypothyroidism chemically induced, Male, Middle Aged, Thyroid Diseases blood, Thyrotropin blood, Thyroxine blood, Triiodothyronine blood, Antimanic Agents adverse effects, Bipolar Disorder drug therapy, Lithium adverse effects, Thyroid Diseases chemically induced
- Abstract
The thyroid functions of 42 subjects with bipolar affective disorder receiving regular lithium therapy were analysed and their thyroid glands were examined by ultrasonography. Following the receipt of lithium therapy (duration 4-156 months), three subjects displayed subclinical hypothyroidism (7.1%), three subclinical hyperthyroidism (7.1%) and one hyperthyroidism (2.4%). Moreover, goitre was detected in 16 (38.1%) subjects. An increase in the conversion of free thyroxine (T4) to free tri-iodothyrosine (T3), which is an indication of mild thyroid dysfunction, was identified in 20 (47.6%) subjects, and was mostly seen in male subjects under 40 years of age and in those having weight gain. In conclusion, some thyroid dysfunctions were observed in the patients treated with lithium.
- Published
- 2002
- Full Text
- View/download PDF
25. Effect of losartan treatment on the proteinuria in normotensive patients having proteinuria due to secondary amyloidosis.
- Author
-
Odabas AR, Cetinkaya R, Selcuk Y, and Bilen H
- Subjects
- Adult, Creatinine blood, Female, Humans, Male, Proteinuria physiopathology, Proteinuria urine, Receptor, Angiotensin, Type 2, Reference Values, Amyloidosis complications, Angiotensin Receptor Antagonists, Antihypertensive Agents therapeutic use, Blood Pressure drug effects, Losartan therapeutic use, Proteinuria drug therapy, Proteinuria etiology
- Abstract
Secondary amyloidosis (AA amyloidosis) is a well known cause of nephrotic syndrome and renal failure. Several studies in patients with nephrotic syndrome have suggested a beneficial effect of angiotensin-converting enzyme inhibitors (ACEI). Angiotensin II (ATII) receptor antagonists effect on the long term is not known. In this study, we intended to study the effect of losartan, as an ATII receptor antagonist, on proteinuria and renal functions in patients with normotensive secondary amyloidosis. In total 44 patients with biopsy proven AA amyloidosis associated with nephrotic proteinuria were included. The first group of patients (n=22) was treated with losartan 50 mg/day. The second group of patients (n=22) did not receive any specific antiproteinuric treatment. Urinary protein loss was effectively lowered by losartan from 4.38 +/- 1.0 to 2.8 +/- 0.61 g/day (p<0.0001), whereas the control group showed a slight fall in proteinuria as 4.21 +/- 1.06 to 4.12 +/- 1.07 g/day (p = 0.176). Hypoalbuminemia improved significantly from 2.52 +/- 0.69 to 2.78 +/- 0.46 g/dl (p = 0.004), in the losartan group, whereas serum albumin had fallen in the control group from 2.44 +/- 0.57 to 2.27 +/- 0.41 (p = 0.041). Serum creatinine increased in the control group from 1.52 +/- 0.42 to 2.39 +/- 0.51 mg/dl (p<0.0001), and in the losartan group from 1.59 +/- 0.50 to 1.84 +/- 0.6 mg/dl (p<0.001), after 24 months of treatment. The ATII receptor blocker losartan is effective in protecting against the progression of nephropathy due to AA amyloidosis. Symptomatic treatment of proteinuria with losartan is therefore to be considered, especially with severe proteinuria even in normotensive patients.
- Published
- 2001
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.